Radiofrequency ablation

Cardiology Applications Drive Dominance in the Radiofrequency Ablation Devices Market, Fueled by Rising Cardiovascular Disease Prevalence - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 19, 2023
Health, Cardiology, United States Census Bureau, Ventricular tachycardia, Neoplasm, Patient, Asset, Ageing, Incidence, Radiofrequency ablation, Arrhythmia, Abdominal ultrasonography, Mortality, Prevalence, Cardiovascular disease, Conditional sentence, Atrial fibrillation, Ablation, Vels Institute of Science, Technology & Advanced Studies, Death, Liver cancer, World Health Organization, Risk, Radio frequency, Cancer, Hospital, Wilford Hall Ambulatory Surgical Center, Center for Economic Studies (U.S. Census Bureau), Osteoporosis, Traction, USD, Safety, Arthritis, Pharmaceutical industry, Medical imaging, Dietary supplement, Health care, Growth

The increasing prevalence of chronic diseases, especially cardiovascular diseases and cancers, coupled with a growing elderly population and technological innovations in these devices, is fueling the demand for radiofrequency ablation devices.

Key Points: 
  • The increasing prevalence of chronic diseases, especially cardiovascular diseases and cancers, coupled with a growing elderly population and technological innovations in these devices, is fueling the demand for radiofrequency ablation devices.
  • Cardiovascular Diseases: A major cause of global mortality, driving the demand for radiofrequency ablation devices.
  • The escalating incidence of cardiovascular diseases is expected to drive the demand for radiofrequency ablation devices, especially in the treatment of atrial fibrillation.
  • Radiofrequency ablation devices are widely used in oncology and cardiology to treat conditions such as tumors and arrhythmias.

STARmed America Launches, Pioneering Thermal Ablation Innovations in North America

Retrieved on: 
Thursday, October 5, 2023
Uterine fibroid, Quality of life, Liver, Health, RF, Patient, FDA, Kidney, RFA, Lung, Electrode, VIVA, Radiofrequency ablation, Pharmaceutical industry, Medical imaging, Thyroid

STARmed Co., Ltd. has been at the forefront of thermal ablation innovations, offering patient comfort through minimally invasive alternatives.

Key Points: 
  • STARmed Co., Ltd. has been at the forefront of thermal ablation innovations, offering patient comfort through minimally invasive alternatives.
  • Starting its journey focusing on Liver Radiofrequency Ablation (RFA), STARmed has since spearheaded itself in Thyroid Radiofrequency Ablation (RFA) technologies and engineered the first thyroid-specific RF electrodes in 2009.
  • "Establishing STARmed America is an integral step in our journey to bring our cutting-edge thermal ablation solutions readily accessible to providers and patients in North America," remarked Henry Shin, CEO of STARmed.
  • With STARmed America, the parent company aims to further solidify its position as a globally recognized and respected brand in the ablation market.

Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett’s Esophagus

Retrieved on: 
Monday, October 2, 2023
Oncology, Health, Surgery, Managed Care, Research, Science, Biotechnology, LGD, AFS, Esophagus, Cancer, Radiofrequency ablation, EAC, Incidence, BE, HGD, Dysplasia, HIV disease progression rates, Patient, Physician, Risk, Report, Annual general meeting, Esophageal cancer, Poster, EET, RFA, Pharmaceutical industry, Medical imaging

The data was presented in a poster at the recent American Foregut Society (AFS) Annual Meeting.

Key Points: 
  • The data was presented in a poster at the recent American Foregut Society (AFS) Annual Meeting.
  • The poster, titled “A Tissue Systems Pathology Test Enables Risk-Aligned Management of Patients with Non-Dysplastic Barrett’s Esophagus: Case Reports from a Gastrointestinal Surgery Center,” can be viewed here .
  • The case study reinforced the ability of TissueCypher to identify NDBE patients at high/intermediate risk for progression to HGD/EAC.
  • Identification of NDBE patients with similar progression risk to LGD enables physicians and their patients to consider risk-aligned upstaging of care to prevent development of EAC and improve their overall health outcomes.

TissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus

Retrieved on: 
Thursday, September 14, 2023
Oncology, Health, Genetics, Other Health, Clinical Trials, Research, Science, University, LGD, Marie Cassidy, SURF, Pathology, Cancer, Radiofrequency ablation, EAC, BE, HGD, Dysplasia, Patient, Standard of care, Physician, Surveillance, Esophageal cancer, Artificial intelligence, Diagnosis, Disease, Medical device, Medical imaging, Gastroenterology

The study aimed to compare the test’s performance against an international panel of 14 expert and 16 community-based, generalist pathologists from five countries.

Key Points: 
  • The study aimed to compare the test’s performance against an international panel of 14 expert and 16 community-based, generalist pathologists from five countries.
  • Use of the TissueCypher test in combination with pathology review identified 80.4% of patients who progressed, indicating that the test can increase the early detection of progressors when used with pathology.
  • Overall, the study demonstrated that TissueCypher can accurately predict progression to HGD or EAC in BE patients who are initially diagnosed with LGD in a community setting.
  • Further, TissueCypher test results can provide an objective solution to variable pathology review, allowing physicians to make more informed management decisions for their patients, which may include upstaging care for patients at high risk for progression and reducing unnecessary interventions in low-risk patients.

Baird Medical Submits Disposable Microwave Ablation Needle and MWA System Application to U.S. FDA for Treatment of Soft Tissue Microwave Ablation

Retrieved on: 
Thursday, August 10, 2023
CDRH, FDA Center for Devices and Radiological Health, MWA, Needle, Radiofrequency ablation, Patient, National Medical Products Administration, Device, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Medical device

GUANGZHOU, China, Aug. 10, 2023 /PRNewswire/ -- Baird Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China, today announced the 510(k) premarket notification submission of the Company's Disposable Microwave Ablation ("MWA") Needle and the Company's MWA System to the U.S. Food and Drug Administration (FDA) for the treatment of soft tissue microwave ablation.

Key Points: 
  • GUANGZHOU, China, Aug. 10, 2023 /PRNewswire/ -- Baird Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China, today announced the 510(k) premarket notification submission of the Company's Disposable Microwave Ablation ("MWA") Needle and the Company's MWA System to the U.S. Food and Drug Administration (FDA) for the treatment of soft tissue microwave ablation.
  • Baird Medical believes MWA technology offers compelling advantages over other treatment options, including shorter operation times, faster patient recovery, reduced procedure costs, and fewer post-surgery complications.
  • Ms. Haimei Wu, Founder and CEO of Baird Medical, said, "Minimally invasive and more affordable treatment solutions represent the future.
  • The Company received recent approval from China's National Medical Products Administration for its Class III disposable MWA needle on July 13, 2023.

New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus

Retrieved on: 
Monday, August 7, 2023
Science, Biometrics, Biotechnology, Research, Oncology, Health, Genetics, Other Health, University, LGD, Marie Cassidy, SURF, Pathology, Radiofrequency ablation, Gastrointestinal Endoscopy, Cancer, SOC, Incidence, BE, American Journal, The American Journal of Gastroenterology, Dysplasia, Patient, Standard of care, Risk, Surveillance, Mortality, Nursing, Pharmaceutical industry, IND

The full study is available here .

Key Points: 
  • The full study is available here .
  • The study results showed the following:
    Using TissueCypher test results to guide patient management decisions, in conjunction with the standard of care (SOC), significantly increased the likelihood of patients receiving appropriate management per their known outcome.
  • Overall, the study results suggest that TissueCypher may be used to standardize the management of BE patients with NDBE, IND and LGD.
  • Use of the TissueCypher test may also improve health outcomes by identifying patients at a low risk of progression who can avoid unnecessary therapy and be managed using surveillance alone.

Dr. Andres Betts Joins Pain Medicine Associates - Mission Viejo, California

Retrieved on: 
Tuesday, July 18, 2023
Pain disorder, University, Long Beach, California, Cranial nerves, Critical Care Medicine (journal), Skiing, Sciatica, Alfred Noble Prize, Spine, Radiofrequency ablation, Suite, Piriformis syndrome, PMA, University of California, Irvine Medical Center, Patient, Physician, Pain Clinic, Associate, Mountaineering, Pain, Diagnosis, Sacral fracture, Bone fracture, General surgery, Nursing, Dentistry, Anesthesiology, Medicine

MISSION VIEJO, Calif., July 18, 2023 /PRNewswire-PRWeb/ -- Pain Medicine Associates (PMA) is pleased to announce that interventional pain management specialist Andres Betts, M.D., has joined the company's Mission Viejo, California pain management practice. He began seeing patients on July 3rd at the office, located at 26137 La Paz Rd, Suite 140, Mission Viejo, CA 92691.

Key Points: 
  • MISSION VIEJO, Calif., July 18, 2023 /PRNewswire-PRWeb/ -- Pain Medicine Associates (PMA) is pleased to announce that interventional pain management specialist Andres Betts, M.D., has joined the company's Mission Viejo, California pain management practice.
  • He began seeing patients on July 3rd at the office, located at 26137 La Paz Rd, Suite 140, Mission Viejo, CA 92691.
  • Dr. Betts is an innovative, board-certified, fellowship trained interventional pain management physician that specializes in the diagnosis and treatment of pain disorders.
  • He founded the Pain Clinic in Bellingham, Washington and Pain MD Medical Associates in San Clemente, California.

Avanos Medical Supports New Interventional Procedure Recommendations from the UK's National Institute of Health and Care Excellence (NICE)

Retrieved on: 
Wednesday, June 28, 2023
Avanos, Arthritis, University Hospitals Coventry and Warwickshire NHS Trust, Quality of life, Trust, Hypoesthesia, Radiofrequency ablation, Pain, Avanos Medical, Patient, NHS trust, NHS, Radio frequency, Osteoarthritis, RFA, NICE, UHCW, National Institute for Health and Care Excellence, Pharmaceutical industry, Nursing

ALPHARETTA, Ga., June 28, 2023 /PRNewswire/ -- Avanos Medical supports the announcement today from the UK's National Institute for Health and Care Excellence (NICE) recommending the use of radiofrequency ablation (RFA) for the treatment of osteoarthritic knee pain.

Key Points: 
  • ALPHARETTA, Ga., June 28, 2023 /PRNewswire/ -- Avanos Medical supports the announcement today from the UK's National Institute for Health and Care Excellence (NICE) recommending the use of radiofrequency ablation (RFA) for the treatment of osteoarthritic knee pain.
  • The radiofrequency energy can be delivered as conventional radiofrequency, cooled radiofrequency or pulsed radiofrequency.
  • "We are extremely pleased with today's interventional procedure recommendation by NICE," commented Dieter Krines, Avanos Vice President & General Manager, Europe.
  • I hope this will now help to increase awareness of this innovative therapy leading to improved outcomes for many more patients."

Avanos Medical Supports New Interventional Procedure Recommendations from the UK's National Institute of Health and Care Excellence (NICE)

Retrieved on: 
Wednesday, June 28, 2023
Avanos, Arthritis, University Hospitals Coventry and Warwickshire NHS Trust, Quality of life, Trust, Hypoesthesia, Radiofrequency ablation, Pain, Avanos Medical, Patient, NHS trust, NHS, Radio frequency, Osteoarthritis, RFA, NICE, UHCW, National Institute for Health and Care Excellence, Pharmaceutical industry, Nursing

ALPHARETTA, Ga., June 28, 2023 /PRNewswire/ -- Avanos Medical supports the announcement today from the UK's National Institute for Health and Care Excellence (NICE) recommending the use of radiofrequency ablation (RFA) for the treatment of osteoarthritic knee pain.

Key Points: 
  • ALPHARETTA, Ga., June 28, 2023 /PRNewswire/ -- Avanos Medical supports the announcement today from the UK's National Institute for Health and Care Excellence (NICE) recommending the use of radiofrequency ablation (RFA) for the treatment of osteoarthritic knee pain.
  • The radiofrequency energy can be delivered as conventional radiofrequency, cooled radiofrequency or pulsed radiofrequency.
  • "We are extremely pleased with today's interventional procedure recommendation by NICE," commented Dieter Krines, Avanos Vice President & General Manager, Europe.
  • I hope this will now help to increase awareness of this innovative therapy leading to improved outcomes for many more patients."

Avanos Medical, Inc. Announces Agreement to Acquire Diros Technology Inc.

Retrieved on: 
Monday, June 19, 2023
Avanos, Radiofrequency ablation, Avanos Medical, Hospital, Acquisition, Patient, Pain management, Growth, EPS, Health, RFA, NYSE, Ted Diro, AVNS, Medical imaging, RF

ALPHARETTA, Ga., June 19, 2023 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced it has entered into a definitive agreement to acquire Diros Technology Inc., a leading manufacturer of innovative radiofrequency (RF) products used to treat chronic pain conditions.

Key Points: 
  • ALPHARETTA, Ga., June 19, 2023 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced it has entered into a definitive agreement to acquire Diros Technology Inc., a leading manufacturer of innovative radiofrequency (RF) products used to treat chronic pain conditions.
  • Based in Toronto, Canada, Diros Technology has been at the forefront of radiofrequency ablation (RFA) technology since its founding.
  • The addition of Diros' unique RF Trident™ technology is expected to further enhance Avanos' pain management treatment options and complement its premium COOLIEF* Cooled Radiofrequency product offering.
  • "The acquisition of Diros Technology strengthens Avanos' leadership position in RF technology by providing a full range of high-quality, differentiated pain management products," said Avanos Chief Executive Officer, Joe Woody.